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Abstract
Sarcoidosis is a multisystem granulomatous disease of unknown etiology
characterized by noncaseating granulomas in involved organs. Organs involved
with sarcoidosis include lymph nodes, skin, lung, central nervous system, and
eye. Only 40-50% of patients with cardiac sarcoidosis diagnosed at autopsy have
the diagnosis made during their lifetime. Cardiac sarcoidosis can manifest itself
as complete heart block, ventricular arrhythmias, congestive heart failure,
pericardial effusion, pulmonary hypertension, and ventricular aneurysms.
Diagnostic tests such as the electrocardiogram, two-dimensional echo-
cardiography, cardiac magnetic resonance imaging, positron emission
tomography scan, radionuclide scan, and endomyocardial biopsy can be helpful
in the early detection of cardiac sarcoidosis. Considering the increased risk of
sudden death, cardiac sarcoidosis is an indication for early treatment with
corticosteroids or other immunosuppressive agents. Other treatments include
placement of a pacemaker or implantable defibrillator to prevent sudden death.
In refractory cases, cardiac transplantation should be considered.
K Ke ey y   w wo or rd ds s: : sarcoidosis, noncaseating granulomas, cardiac sarcoidosis.
Introduction
Sarcoidosis is a multisystem granulomatous disease of unknown
etiology characterized by the presence of noncaseating granulomas in the
involved organs. The prevalence is 10-40/100,000 persons in the United
States and Europe with an increased prevalence of sarcoidosis in African-
Americans compared to Caucasians with a ratio ranging from 10-17 : 1 [1].
The Scandinavian population has a higher prevalence of sarcoidosis than
other whites [2]. 
Sarcoidosis is more prevalent in women than in men. Virtually any body
tissue may be involved. Organs commonly involved with sarcoidosis include
lymph nodes, skin, lung, central nervous system, and eye. Although many
patients may not manifest symptoms at the time of diagnosis, some
patients present with systemic symptoms such as fatigue, anorexia, weight
loss, and fever. Many patients report dyspnea on exertion, retrosternal
chest pain, and cough. In 20% to 50% of patients with more acute
presentations, the constellation of erythema nodosum, bilateral hilar
lymphadenopathy, and polyarthralgia (Lofgren’s syndrome) is seen. In the
United States, more than half of patients present with chronic respiratory
symptoms and few constitutional symptoms [2].
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Cardiac involvement in sarcoidosis occurs in 20-
30% of patients in pathology series [3]. Cardiac
involvement in patients with sarcoidosis is being
increasingly recognized and is associated with
a poor prognosis. Silverman et al. reviewed 84
autopsy cases of pulmonary sarcoidosis and found
myocardial granulomas in 27% of patients [4].
Cardiac  involvement  may  be  high  as  58%  in
Japanese patients with sarcoidosis [5, 6] and may
be responsible for as many as 85% of deaths of
Japanese patients with sarcoidosis [6, 7]. Despite
these findings, only 5% of patients with sarcoidosis
have clinical manifestations of cardiac disease, and
only 40-50% of patients with cardiac sarcoidosis at
autopsy have the correct diagnosis made during
their lifetime. 
The  etiology  of  cardiac  sarcoidosis  remains
unknown.  Environmental,  occupational,  and
infectious causes have been hypothesized. These
agents may act as immunologic triggers in ge  -
netically predisposed individuals. A multicenter case
controlled study did not discover a single pre  -
dominant  cause  of  sarcoidosis,  but  identified
several exposures that were linked to sarcoidosis
risk  including  agricultural  employment  and
exposure to insecticides or microbial bioaerosols
[8]. A number of infectious organisms, including
Mycobacteria, Propionibacteria, Borrelia, Rickettsia,
and Herpes virus have been implicated as possible
etiologies of sarcoidosis [9]. A provocative pilot
study reported the empiric use of anti-fungal agents
with corticosteroids for 3-6 months in 18 patients
resulted in improvement of clinical symptoms, chest
X-ray infiltration, and pulmonary function [10]. The
role of infectious organisms in the etiology of
sarcoidosis remains to be clarified. Myocardial
sarcoidosis affects young and middle-aged patients
without sex predilection. Myocardial involvement
may occur in 25% of patients with sarcoidosis in
the United States, and may account for as many as
13-25% of deaths from sarcoidosis. 
Pathology
The etiology of sarcoidosis is unknown, but the
principal  inciting  event  leads  to  granuloma
formation, which can then either resolve or progress
to fibrosis. Sarcoidosis requires at least 3 major
events: exposure to antigen; acquired cellular
immunity directed against the antigen mediated
through  antigen  presenting  cells  and  antigen
specific T lymphocytes; and the appearance of
immune  effector  cells  that  promote  a more
nonspecific inflammatory response. 
The  characteristic  lesion  of  sarcoidosis  is
a discrete, compact, noncaseating epitheloid cell
granuloma.  The  granuloma  consists  of  highly
differentiated  mononuclear  phagocytes  and
lymphocytes. Infectious and environmental agents
have been implicated as potential antigens. These
antigens are thought to trigger primarily the helper
inducer T cells leading to formation of granuloma
lesions. Early in the disease, sarcoid infiltrate mainly
consist  of  mononuclear  phagocytes  and  CD4
positive T cells with a T helper Type 1 response,
secreting interleukin-2 and interferon-γ. At a later
stage of lesion evolution, there is a shift of cytokine
profile to that of T helper type 2 response which
has been demonstrated during the fibroblastic
phase of the granuloma and is believed to exert
anti-inflammatory  effects  and  result  in  tissue
scarring (Figure 1). Furthermore, high concentrations
of interleukin-6 are found in the circulation at the
onset  of  disease  and  before  the  initiation  of
immunosuppressive therapy, but not thereafter.
Interleukin-6 is thought to be involved in the
maintenance of inflammation by inducing the
proliferation of T cells [11].
Clinical  manifestations  of  sarcoidosis  are
dependent on both the profusion and location of
granulomas. Cardiac sarcoidosis is associated with
noncaseating granulomas which may involve the
left ventricular free wall, basal ventricular septum,
right ventricle, papillary muscles, right atrium, and
left atrium [12]. The pathologic features include 
3 suc  cessive histological stages: edema, granu  -
lomatous infiltration, and fibrosis leading to post-
inflammatory  scarring.  Pathologic  samples  of
F Fi ig gu ur re e   1 1. .   This figure illustrates the pathogenesis of
cardiac sarcoidosis
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myocardium involved with sarcoidosis reveal the
presence of numerous lymphocytes located at the
border zones around the granulomas. A dense
band  of  fibroblasts,  collagen  fibers,  and  pro  -
teoglycans  usually  encase  this  aggregate  of
inflammatory cells [12]. 
Genetic factors
A Case Controlled Etiologic Sarcoidosis Study
(ACCESS) concluded that first-degree relatives of
patients with sarcoidosis had a relative risk of
sarcoidosis that was five times that of control
subjects [13]. Genetic factors appear to play a role
in defining the risk of the disease. On exposure to
antigens, some individuals trigger an exaggerated
cellular immune response and the formation of
granulomas  which  may  be  due  to  genetic
predisposition. The genetic factors also determine
the pattern of disease, its severity, and prognosis.
Monozygotic twins are more commonly affected
than dizygotic twins. Familial clusters occur with
a rate of at least 19% in affected black families 
and 5% in white families. Multiple serologic studies
have identified primary associations with class 1
HLA-A1 and B8 and class II HLA-DR3 in whites [2].
The occurrence of cardiac sarcoidosis in Japanese
female patients is associated with the presence of
HLA-DQB1*0601 and the allele TNFA2 [14, 15].
Clinical manifestations
Sarcoidosis can be widespread, or limited to
involvement of only a single system at a time. Many
asymptomatic cases may be discovered by chest
radiography which may or may not progress to
clinically symptomatic disease. However, a pro  -
portion of patients may present with systemic
symptoms which include fever, fatigue, malaise, and
weight loss. Intrathoracic involvement occurs in
more than 90% of patients. About one-third of
patients have palpable peripheral lymph nodes.
Abnormalities of liver function tests are common.
Cutaneous  involvement  may  occur  in  25%  of
patients and may present as erythema nodosum,
granulomatous nodule, or papules. Other organ
systems may be involved including eye, nervous
system, gastrointestinal tract, hematological, parotid,
endocrine, reproductive organs, and kidneys.
Cardiac  involvement  occurs  in  20-27%  of
sarcoid patients in the United States and may be
as high as 58% in Japan [6]. If cardiac manifes  -
tations occur in a patient with multi-systemic
sarcoidosis, the diagnosis, although circumstantial,
is strongly suspected. However, when cardiac
dysfunction  is  the  only  manifestation  of
sarcoidosis,  the  diagnosis  is  frequently  not
entertained [16]. The patients who come with only
the symptoms in Table I and are suspected to
have cardiac sarcoidosis should undergo a detailed
investigation  including  myocardial  biopsy  if
needed. Even when the diagnosis is considered,
it is not often confirmed because of unavailability
of specific diagnostic tests. 
Early diagnosis and treatment is essential since
treatment  improves  prognosis.  The  failure  to
diagnose cardiac sarcoidosis is partly attributable
to the relative rarity of clinically apparent forms of
the disease. Only 40-50% of patients with cardiac
sarcoidosis at necropsy have clinical evidence of
myocardial involvement during lifetime [4]. Serious
cardiac dysfunction is detected in 5% to 10% of
cases. In a significant proportion of patients with
cardiac  sarcoidosis,  the  initial  presentation  is
sudden death. In 37% of patients with cardiac
involvement,  there  were  no  clinical  signs  or
symptoms of the disease [4].
Complete heart block 
Complete heart block is one of the most com  -
mon finding in patients with clinically evident
cardiac sarcoidosis and occurs at a younger age in
patients with sarcoidosis than in patients with
complete heart block of other causes [17]. Complete
heart block (Figure 2) and bundle branch block have
been reported in 23-30% and 12-32%, respectively
of patients with myocardial sarcoidosis. They are
caused by involvement of the basal septum by scar
tissue, granulomas, or involvement of the nodal
artery causing ischemia in the conduction system
[6].  Sudden  death  may  be  a direct  result  of
complete heart block. For Japanese patients, notably
women over 50 years of age, complete heart block
is frequent and leads to the diagnosis of cardiac
sarcoidosis in 11% of cases [18]. Patients with
sarcoidosis who present with syncope or pre  -
syncope should be evaluated for complete heart
block  with  electrocardiographic  and  Holter
monitoring. Sarcoidosis should be included in the
evaluation of patients with syncope, especially
when it occurs in a younger patient.
Ventricular arrhythmias
Sudden death caused by ventricular tachyar  -
rhythmias or complete heart block may account for
25-65% of deaths caused by cardiac sarcoidosis,
C Co om mp pl le et te e   h he ea ar rt t   b bl lo oc ck k 23-30%
B Bu un nd dl le e   b br ra an nc ch h   b bl lo oc ck k 12-32%
V Ve en nt tr ri ic cu ul la ar r   t ta ac ch hy yc ca ar rd di ia a 23%
C Co on ng ge es st ti iv ve e   h he ea ar rt t   f fa ai il lu ur re e 25-75%
S Su ud dd de en n   d de ea at th h 25-65%
T Ta ab bl le e   I I. . Prevalence of cardiac findings in cardiac
sarcoidosis
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F Fi ig gu ur re e   2 2. .   This figure illustrates complete heart block with an atrial rate of 76 beats per minute and an idioventricular
pacemaker with a ventricular rate of 26 beats per minute
and this may be the initial presentation in 40% of
patients with cardiac sarcoidosis [19]. Ventricular
tachycardia  is  also  one  of  the  most  frequent
arrhythmia noted in cardiac sarcoidosis, and one
study demonstrated a 23% incidence of ventricular
tachycardia (Table I) [20]. Sarcoid granulomas may
serve  as  foci  for  abnormal  automaticity  or  to
disperse both ventricular activation and recovery
processes that can cause reentrant tachycardias.
The  reentrant  pathway  can  result  from  active
granulomatous inflammation but also can be found
in  association  with  the  healing  of  cardiac
granulomas in the inactive phase of the disease.
Atrial arrhythmias are less common than ventricular
arrhythmias, occurring in 15-17% of cases. They are
often the result of atrial dilatation or pulmonary
involvement  rather  than  the  result  of  atrial
granulomas [12].
Congestive heart failure
Progressive heart failure accounts for 25% to
75% of cardiac deaths in patients with cardiac
sarcoidosis [21]. Heart failure may be secondary to
left- sided cardiac involvement with either systolic
or diastolic dysfunction and can occur when there
is extensive infiltration of the myocardium by non-
caseating  granulomas.  Differentiating  cardiac
sarcoidosis from idiopathic dilated cardiomyopathy
(IDC) can be difficult. Yazaki et al. retrospectively
compared 15 patients having cardiac sarcoidosis
and left ventricular systolic dysfunction to 30
patients with IDC [22]. The sarcoidosis group had
a significantly higher frequency of complete heart
block (67% vs. 0%), right bundle branch block (57%
vs.  17%),  and  abnormal  left  ventricular  wall
thickness (73% vs. 17%).
Pericardial effusion/valvular
involvement/ventricular aneurysm
Pericardial involvement is uncommon even in
the presence of extensive myocardial infiltration. It
is observed in fewer than 10% of patients with
cardiac sarcoidosis, and these patients usually
remain asymptomatic. Small pericardial effusions
detected by echocardiography were found in 19%
of patients with sarcoidosis [23, 24]. Direct valvular
involvement occurs in fewer than 3% of patients,
but valvular incompetence secondary to papillary
muscle dysfunction can be seen in approximately
68% of patients [25]. Mitral regurgitation may result
from papillary muscle dysfunction or dilatation of
the left ventricle secondary to diffuse disease.
Ventricular  aneurysms  occur  in  10%  of  the
patients with sarcoidosis. The anterior and septal
wall segments are more commonly affected, and it
is unusual that wall motion of only the apical
segment is reduced. Extension of ventricular lesions
may  lead  to  aneurysm  formation.  Long-term
corticosteroid therapy can heal sarcoid granulomas,
replacing  myocardium  with  fibrous  tissue,  but
steroid therapy has been associated with ventricular
aneurysms [26, 27]. Nonetheless, corticosteroids
should  be  used  if  clinically  indicated  since
ventricular aneurysm is common in untreated
patients with myocardial sarcoidosis. Myocardial
aneurysms may be associated with frequent and
complex ventricular arrhythmias. These arrhythmias
may  resolve  after  resection  of  the  aneurysm.
Impaired  arterial  perfusion  in  the  vicinity  of
granulomas may impair the local delivery of anti-
arrhythmic drugs. Therapy is also complicated by
the presence of certain acidic acute phase reactants
that bind to drugs with high pK, thus interfering
with serum levels. 
Pulmonary hypertension and cor pulmonale
Pulmonary hypertension (PH) is a predictor of
poor outcome in sarcoidosis. Shorr et al. reported
that the frequency of PH was as high as 73.8% in
363 advanced sarcoidosis patients listed for lung
transplant [28]. In a study by Tomhiro et al., the
frequency of PH in Japanese sarcoidosis patients
who were followed in an outpatient clinic was 5.7%
[29]. There are multiple mechanisms for PH in
sarcoidosis.  Pulmonary  hypertension  can  be
a consequence of impaired forward flow and result
from poor left ventricular function. Pulmonary
hypertension may occur in patients with pulmonary
sarcoidosis,  especially  those  with  hypoxic
vasoconstriction,  resulting  in  cor  pulmonale.
Alveolar hypoxia, irrespective of the cause, not only
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causes vasoconstriction but can result in pulmonary
vascular remodeling. At times elevated pulmonary
arterial pressures are associated with normal or
near normal lung function and arterial blood gases.
This may suggest the presence of an intrinsic
sarcoid  vasculopathy.  Encroachment  of  the
pulmonary  vasculature  by  intimal  and  medial
infiltration by noncaseating granuloma and extrinsic
compression of pulmonary arteries by enlarged
mediastinal lymph nodes can also cause PH [30].
Pulmonary hypertension has been associated with
more severe pulmonary involvement as reflected
by chest X ray and pulmonary function tests. There
may be multiple causes of sarcoid-associated PH,
and  therefore  these  patients  should  undergo
a complete and careful diagnostic work-up.
Diagnosis
Only after a thorough clinical evaluation docu  -
menting a syndrome consistent with sarcoidosis
and biopsy documentation of the presence of non-
caseating granulomas can a diagnosis of sarcoidosis
be  made.  All  other  causes  of  non-caseating
granulomas must be reasonably excluded. The
presence of signs, symptoms, or findings sugges  -
tive of cardiac involvement warrant additional
asses  sment to confirm presence of cardiac sarco  -
idosis [2].
Endomyocardial biopsy
A definite diagnosis of cardiac sarcoidosis can
be made by endomyocardial biopsy. The sensitivity
of  endomyocardial  biopsy  for  non-caseating
granulomas is low, usually less than 20% [31]. It is
believed that this low sensitivity is a consequence
of patchy myocardial involvement which frequently
involves the intraventricular septum and the left
ventricle. Despite its low sensitivity, early myocardial
biopsy can be considered when the diagnosis of
cardiac sarcoidosis is entertained. Endomyocardial
biopsy can help to rule out other causes of cardiac
myopathy and may confirm the diagnosis of cardiac
sarcoidosis [2]. In the absence of granulomas, it
might be difficult to distinguish between cardiac
sarcoidosis and idiopathic giant cell myocarditis [32]
as both of these diseases have giant cells and are
associated with ventricular tachycardia and heart
block.  The  differential  diagnosis  will  include
connective  tissue  diseases  like  Lyme  disease,
rheumatoid arthritis, dermatomyositis, cardiac
amyloidosis and alcohol related cardiomyopathy,
but these can be distinguished based on clinical
findings.
Electrocardiographic and Holter monitoring
The electrocardiogram (ECG) should be part of
the  routine  evaluation  of  the  patient  with
a diagnosis of sarcoidosis. The electrocardiogram
changes are found in as many as 50% of patients
with systemic sarcoidosis. This may occur without
clinical evidence of cardiac involvement [33-35].
Although the ECG is an important part of patient
evaluation, it is often nondiagnostic or non-specific.
In a study by Suzuki et al. 24-h Holter monitoring
detected cardiac sarcoidosis with a sensitivity of
67% and a specificity of 62% when ventricular
ectopic beats numbered more than 100/day [36].
An electrical abnormality even as insignificant as
sinus tachycardia should be investigated as it may
indicate myocardial infiltration. QT dispersion (QTd),
the maximal interlead difference in QT interval on
the surface 12 lead ECG, may be a predictor of
sudden cardiac death. A preliminary study of 35
patients with systemic sarcoidosis, the subgroup
with cardiac sarcoidosis had a significantly greater
QTd than the noncardiac sarcoidosis group and
a control  group.  The  incidence  of  premature
ventricular complexes on ECG in a limited follow-
up group was greater in the cardiac sarcoidosis
group than in the noncardiac sarcoidosis group [37].
Carvedilol has been reported to significantly reduce
QTd [38].
Doppler echocardiography
Echocardiography is an important tool in the
diagnosis and surveillance of patients with cardiac
sarcoidosis. In a recent study of 41 patients, Doppler
echocardiography was abnormal in 67% of patients
with dilated cardiomyopathy in 32% of patients
(Figure 3), with abnormal left ventricular relaxation
in 29% of patients, and with diffuse or localized
dyskinesia or hypokinesia in 26% of patients [39].
Two-dimensional echocardiographic abnormalities
for cardiac sarcoidosis include abnormal septal
thickening or thinning, dilatation of the left ventricle
(Figure 3), and systolic dysfunction of the left
ventricle [25]. Doppler echocardiography may also
identify left ventricular diastolic dysfunction which
F Fi ig gu ur re e   3 3. .   This figure is a 2-dimensional echocardio  -
gram showing a dilated cardiomyopathy. The left
ventricular internal dimension at the end of diastole
is 6.6 cm
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can be an early sign of granulomatous involvement
of the myocardium [40]. Echocardiography may not
detect mild localized myocardial abnormalities
which occur in the early stage of cardiac disease.
The  cycle  dependent  variation  of  myocardial
integrated  backscatter  (CV-IB)  is  another  new
technique. It can be decreased in the basal septum
in patients with cardiac sarcoidosis even in the
absence  of  2-dimensional  echocardiographic
abnormalities  [41].  Mechanisms  may  include
decreased regional myocardial contraction function,
altered myocardial acoustic properties influenced
by  myocytolysis,  and  cell  infiltration  in  the
myocardium. This may be a useful method to detect
early  myocardial  involvement  in  patients  with
sarcoidosis.
Radionuclide studies
Nuclear medicine imaging is another important
tool in the diagnosis of cardiac sarcoidosis. The
fibrogranulomatous lesions in the myocardium
display segmental areas of decreased uptake in
nuclear imaging. Most useful studies are performed
with thallium 201 and technetium 99m sestamibi
[42]. Improvement or complete resolution with
dipyridamole differentiates cardiac sarcoidosis from
coronary artery disease in which defects at rest
worsen or fail to improve with exercise, dipyri  -
damole,  or  adenosine.  Myocardial  perfusion
abnormalities in sarcoidosis are reversible after
pharmacological dilation which may be due to
possible  microvascular  vasoconstriction  in
myocardial sarcoidosis. This phenomenon is referred
to as “reverse distribution” [43, 44]. 
Thus, in order to assess cardiac sarcoidosis,
a baseline  resting  myocardial  scan  should  be
performed in addition to a scan after dipyridamole
infusion.  Sestamibi  single-photon  emission
computer tomography (SPECT) is more sensitive
than  thallium  in  the  diagnosis  of  myocardial
sarcoidosis. However this modality is not specific
for cardiac sarcoidosis. Gallium is highly sensitive
for cardiac sarcoidosis since it accumulates in the
inflamed  areas  and  is  useful  in  judging  the
response of the disease to steroid therapy. Unfortu  -
nately, myocardial gallium SPECT images are not
sufficiently clear in distinguishing gallium uptake
in  the  myocardium  from  that  in  the  lung  or
mediastinum. Therefore, the clinical usefulness of
gallium SPECT scanning has not been adequately
established [45]. 
A study by Kasawa et al., showed that the use
of  dual  SPECT  scanning  with  gallium  and
technetium could be a useful diagnostic imaging
technique and improved the diagnostic specificity
of  gallium  SPECT  for  the  diagnosis  of  cardiac
sarcoidosis [46]. Studies have shown that myo  -
cardial uptake of gallium may predict respon  sive  -
ness to steroid therapy [45].
Magnetic resonance imaging 
Sarcoid  infiltrates  are  visible  by  magnetic
resonance imaging (MRI) as a zone of increased
intramyocardial signal intensity. These are more
pronounced on T2 weighted images because of the
edema  associated  with  inflammation  and
granulomatous  lesions.  These  images  can  be
enhanced on gadolinium diethylene pentaacetic
acid enhanced MRI. Focal myocardial thickening is
often seen as a result of the edema [47-50].
Increased  signal  intensity  on  T2  weighted
sequences  without  myocardial  thickening  and
without gadolinium uptake can also be observed.
This feature may be noticed in patients already
receiving corticosteroids or on the follow-up MRI
after  treatment.  Delayed  enhanced  MRI  is
considered  a useful  method  for  the  early
identification  of  cardiac  sarcoidosis.  Delayed
hyperenhancement is frequently associated with
a reduction of regional wall motion and thallium-
201  perfusion  defects.  The  area  with  delayed
enhancement represents myocardium that has
been replaced by the fibrogranulomatous tissue of
sarcoidosis, resulting in decreased wall motion [51].
Positron emission tomography
Positron emission tomography (PET) can also
identify sarcoid cardiac involvement and assess
severity. The PET scan may be useful in patients
with a pacemaker or cardioverter-defibrillators
implanted who are unable to undergo MRI because
of the safety concerns related to potential adverse
effects  on  the  device  arising  from  the  strong
magnetic and radiofrequency forces generated by
MRI. These include the possibility of erratic and
inappropriate device functioning during or after the
scan, over-sensing that can cause high rate pacing
or thermal damage to the device, and induced
voltages on leads that can cause over- and under-
sensing. Moreover, combined effects can cause
component failures, mechanical vibration, and
device damage [52]. 
Yamigishi et al. studied 17 patients with cardiac
sarcoidosis  using  PET  [53].  Positron  emission
tomography imaging was positive in 14 (82%) of
these patients [53]. Only 6 of 17 patients (35%)
showed 201 thallium defects, and only 3 of 17
patients  (18%)  revealed  abnormal  67  gallium
accumulation. In addition, the patients who were
treated with steroids showed a decrease in uptake
and hence improvement on PET. Positron emission
tomography has the potential to be an important
tool in the diagnosis and monitoring of patients
with cardiac sarcoidosis.
Other studies
Cardiac catheterization is indicated in patients
with sarcoidosis to rule out coronary artery disease
Cardiac sarcoidosis552 Arch Med Sci 4, August / 2011
in patients with chest pain, congestive heart failure,
or abnormal imaging. In the presence of normal
coronary arteries, the perfusion defects on thallium
scanning in a patient with sarcoidosis strongly point
toward  the  existence  of  cardiac  sarcoidosis.
However, sarcoid patients with cardiac dysfunction,
ECG abnormalities, or thallium-201 imaging defects
should be presumed to have cardiac sarcoidosis
even  when  endomyocardial  biopsy  shows  no
granulomas.
Cardio-pulmonary exercise studies, including
measurement of peak oxygen consumption, can be
very helpful in the evaluation for heart failure [54].
Treatment and prognosis
I Im mm mu un no os su up pp pr re es ss si iv ve e   t th he er ra ap py y
Cardiac sarcoidosis is an indication for treatment
because  of  increased  risk  of  sudden  death.
Treatment  is  given  to  reduce  inflammation.
Corticosteroids, the most common initial therapy,
should be started in patients with a definite or
strong probability of cardiac sarcoidosis on different
imaging studies, even with a negative myocardial
biopsy. Chiu et al. showed that long- term steroid
use in patients with a left ventricular ejection
fraction (LVEF) > 55% may prevent LV remodeling
and  altered  cardiac  function.  Steroids  most
benefited those patients with a LVEF < 54% who
showed significant reduction in LV volumes and
LVEF improvement [55]. In patients with a LVEF 
< 30%, steroid therapy did not improve the LV
volume or function. These investigators concluded
that in early or middle stage disease, steroid therapy
may be protective or therapeutic but may not be
as effective in the late stages. 
The severity of congestive heart failure is the
most powerful prognostic predictor of survival in
steroid treated patients with cardiac sarcoidosis.
Yazaki et al. reported that the 5-year survival was
about  90%  in  steroid  treated  patients  with
preserved systolic function [21, 22]. There was no
significant difference in survival curves for patients
treated with a high initial dose vs. a low dose of
steroids. It is reasonable to start a steroid dose with
prednisone 60-80 mg a day and taper the dose over
6 months to a dose of 10-mg a day. If the disease
appears to be improved and dormant, then the
steroids can be slowly tapered further. At any sign
of recurrence, steroids should be started at the dose
of 60 mg/day or higher. Long-term corticosteroid
therapy is often required.
Smedema et al. concluded that once symp  -
tomatic cardiac sarcoidosis develops in pulmo  nary
sarcoidosis patients, the prognosis becomes very
poor.  In  contrast  with  asymptomatic  cardiac
sarcoidosis, the prognosis of asymptomatic cardiac
involvement in patients with pulmonary sarcoidosis
is better. Therefore, it is appropriate to screen
pulmonary sarcoidosis patients with an electro  -
cardiogram and clinical evalution and reserve more
specialized  cardiac  evalution  for  those  with
abnormalities [56]. 
Treatment with methotrexate, azathioprine, or
cyclophosphamide can be used as steroid sparing
agents and in those whose disease is refractory to
high-dose steroids [57, 58]. Tumor necrosis factor
is  critical  in  the  genesis  and  maintenance  of
granulomatous inflammation. Case reports have
described cardiac conduction abnormalities which
improved after use of infliximab, a tumor necrosis
factor alpha inhibitor [59]. There is no consensus
on the duration of therapy, and recurrence can
occur after cessation of therapy. There are no
reported randomized controlled trials describing the
superiority of one treatment over another. A com  -
monly used approach would be to start treatment
with corticosteroids with addition of immuno-
suppressive agents in refractory cases. In cases
where steroids are contraindicated, use of immuno  -
suppressive  agents  would  be  given  as  initial
therapy.
O Ot th he er r   t th he er ra ap pi ie es s
Ventricular tachycardia is a common compli  -
cation, and steroids have usually failed to prevent
ventricular tachycardia. Antiarrhythmic drug therapy
for ventricular tachycardia in patients with cardiac
sarcoidosis  is  associated  with  a high  rate  of
recurrence or sudden death. Amiodarone use in this
group of patients may be limited by the occurrence
of pneumonitis and/or pulmonary fibrosis. These
drug-induced  pulmonary  changes  are  indis  -
tinguishable  radiographically  from  pulmonary
sarcoidosis and may compromise the patients’
respiratory status. β-Blockers have been shown to
increase the incidence of heart block in patients
with cardiac sarcoidosis. Given these limitations,
implantation  of  an  implantable  cardioverter
defibrillator  should  be  considered  as  primary
therapy  in  such  patients.  The  indications  for
permanent pacing are similar to those in patients
without cardiac sarcoidosis. Permanent pacing is
effective in the prevention of sudden cardiac death
and in advanced atrioventricular block and other
bradyarrhythmias. 
Cardiac transplantion
Cardiac transplantation is reserved for end-stage
disease unresponsive to medical therapy [60]. Major
indications for cardiac transplantation are resistant
ventricular tachyarrhythmias and severe intractable
heart failure, especially in younger patients. Cardiac
sarcoidosis  results  in  progressive  fibrosis  and
scarring leading to ventricular dysfunction. Patients
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with stage D heart failure who are refractory to
treatment with angiotensin converting enzyme
inhibitors, angiotensin receptor blockers, β-blockers
and diuretics should be considered for cardiac
transplantation [61]. Cardiac transplantation can be
avoided if corticosteroid treatment is started before
the  occurrence  of  severe  systolic  dysfunction.
Sarcoidosis can recur in the transplanted heart and
has been documented to recur 24 weeks to 19
months  after  transplantation.  Transmission  of
sarcoidosis from an allograft donor, who was not
known to have sarcoidosis, to its recipient has been
reported [62]. An increased dosage of steroids may
be required to achieve complete resolution in all
recurrences after transplantation.
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